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Abstract Among the hereditary cerebellar ataxias (CAs),
there are at least 36 different forms of autosomal dominant
cerebellar ataxia (ADCAs), 20 autosomal recessive cere-
bellar ataxias (ARCAs), two X-linked ataxias, and several
forms of ataxia associated with mitochondrial defects.
Despite the steady increase in the number of newly dis-
covered CA genes, patients, especially those with putative
ARCAs, cannot yet be genotyped. Moreover, in daily
clinical practice, ataxia may present as an isolated cere-
bellar syndrome or, more often, it is associated with a
broad spectrum of neurological manifestations including
pyramidal, extrapyramidal, sensory, and cognitive dys-
function. Furthermore, non-neurological symptoms may
also coexist. A close integration between clinical records,
neurophysiological, neuroradiological and, in some
instances, biochemical findings will help physicians in the
diagnostic work-up (including selection of the correct
genetic tests) and may lead to timely therapy. Some
inherited CAs are in fact potentially treatable, and the
efficacy of the therapy is directly related to the severity of
the cerebellar atrophy and to the time of onset of the dis-
ease. Most cases of CA are sporadic, and the diagnostic
work-up remains a challenge. Detailed anamnesis and deep
investigation of the family pedigree are usually enough to
discriminate between acquired and genetic conditions. In
the case of ADCA, molecular testing should be guided by
taking into account the main associated symptoms. In
sporadic cases, a multi-disciplinary approach is needed and
should consider the following points: (1) onset and clinical
course; (2) associated features; (3) neurophysiological
parameters, with special attention to the occurrence of
peripheral neuropathy; (4) neuroimaging results; and (5)
laboratory findings. A late-onset sporadic ataxia, in which
other possible causes have been excluded by following the
proposed steps, might be attributable to metabolic disor-
ders, which in some instances may be treatable. In this
review, we will guide the reader through the labyrinth of
CAs, and we propose a diagnostic flow chart.
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Introduction
The ‘cerebellar ataxias’ (CAs) comprise a wide spectrum
of neurological disorders, with ataxia as the main symp-
tom. Ataxia is defined as imbalance and incoordination
(e.g., gait ataxia, truncal ataxia) or dysmetria and incoor-
dination of a limb while performing a task (limb ataxia).
Gait ataxia is usually secondary to a dysfunction or lesion
of the cerebellum or its connections, but patients can also
have gait ataxia from peripheral sensory impairment [2].
Neurological examination usually provides an accurate
distinction between the two forms [26]. Moreover, CA is
typically accompanied by other signs of cerebellar dys-
function, including abnormal eye movements (hypometric
or hypermetric saccades, saccadic pursuits), nystagmus of
varying types, dysarthria, dysmetria (with kinetic tremor),
and dysdiadochokinesis [2].
Once acquired conditions leading to CA are ruled out
(see Table 1), making an accurate aetiological diagnosis of
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ataxia may be a challenge, given the overlap in phenotypes
and the various presentations of CAs.
Genetic ataxias are frequently chronic and, usually,
progressive diseases. Very rarely, genetic ataxias may be
episodic (only partially covered in this revision; for more
details, see [12]). In apparently sporadic late-onset cases,
genetic ataxias can be difficult to discriminate from non-
genetic forms, such as multiple system atrophy [20] or
progressive supranuclear palsy with predominant CA [17],
even though magnetic resonance imaging (MRI) may help
physicians to reach the correct diagnosis [21]. Reliable
determination of the transmission mode may also require a
detailed assessment of the family members [4], and a fol-
low-up period may be needed for an accurate differential
diagnosis [44].
A large epidemiological study recently showed that
hereditary CAs had a prevalence of 8.9 per 100,000 (5.6 for
dominant and 3.3 for recessive ataxias) in a Portuguese
population. Machado–Joseph disease (spinocerebellar
ataxia type 3; SCA3), Friedreich ataxia and ataxia with
oculomotor apraxia were the most frequent forms [3].
Here we focus our attention on the most common
genetic forms of CA. Among the presented monogenic
causes of ataxia, the diseases that are most frequently
encountered in adult neurological practice are Friedreich
disease, polyglutamine expansion SCAs and mitochondrial
disorders. Table 2 reports the clinical, neuroradiological
and biochemical ‘red flags’ for those diseases.
Finally, we also provide a proposed diagnostic flow
chart (‘the ball of thread’ of Ariadne) with the intent to
help the neurologist Theseus to find his way out of the
Minotaur’s ataxic maze.
Mitochondrial ataxias
The most crucial task of the mitochondrion is the genera-
tion of energy as adenosine triphosphate (ATP), by means
of the electron transport chain. This metabolic pathway is
under the control of both nuclear (nDNA) and mitochon-
drial (mtDNA) genomes. Mitochondrial diseases are a
group of disorders caused by impairment of the mito-
chondrial respiratory chain. The effects of mutations which
affect the respiratory chain may be multisystemic, with
involvement of visual and auditory pathways, heart, central
nervous system, and skeletal muscle. The estimated prev-
alence of mitochondrial disorders is 10–20 in 100,000.
They are, therefore, one of the most common neuro-genetic
conditions.
The genetic classification of mitochondrial disorders
distinguishes disorders due to defects in mtDNA from
those due to defects in nDNA [25]. The diagnostic process
of mitochondrial diseases starts with patient and family
history and with physical and neurologic examination.
‘Red flags’ for mitochondrial diseases are short stature,
neurosensory hearing loss, ptosis, ophthalmoplegia, axonal
neuropathy, diabetes mellitus, hypertrophic cardiomyopa-
thy and migraine. Diagnosis of mitochondrial diseases
requires a complex approach including: measurements of
serum lactate; electromyography; magnetic resonance
spectroscopy; muscle histology and enzymology; and
genetic analysis [25]. The treatment of most mitochondrial
diseases is still inadequate. In this section we discuss the
well-defined forms of mitochondrial disease that most
frequently manifest as CA (‘‘Mitochondrial ataxias’’) [25].
mtDNA point mutations
Point mutations in mtDNA are inherited according to the
rules of mitochondrial genetics (maternal inheritance, het-
eroplasmy and the threshold effect, mitotic segregation).
Each cell contains multiple copies of mtDNA (poly-
plasmy), which in normal individuals are identical to one
another (homoplasmy). Heteroplasmy refers to the coex-
istence of two populations of mtDNA––normal and muta-
ted. Mutated mtDNA in a given tissue has to reach a
minimum critical number before oxidative metabolism is
impaired severely enough to cause dysfunction (threshold
effect) [25].
Myoclonic epilepsy with ragged red fibres (MERRF) has
a variable onset and is mostly characterized by myoclonus
and myopathy (with signs of mitochondrial dysfunction);
CA is common [25]. Generalized seizures are another
possible adjunctive feature. This syndrome has been asso-
ciated with various mtDNA point mutations, the most
frequent of which are A8344G and T8356C in tRNA
lysine. Ito and co-workers [16] reported three MERRF
















Neoplastic disorder Cerebellar tumour, Muir–Torre syndrome
Endocrine Hypothyroidism
Structural disease Chiari malformations, agenesis,
hypoplasias, dysplasias
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patients (with A8344G mutation) in whom CA was the first
symptom; conventional brain MRI showed atrophy of the
superior cerebellar peduncles and the cerebellum in all
patients, and brainstem atrophy in two patients. A recent
large survey of A8344G patients showed that myoclonus
was more strictly associated with ataxia than with gen-
eralized seizures [24], suggesting that MERRF could be
better defined as a myoclonic ataxia rather than a myo-
clonic epilepsy [23].
Mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes syndrome (MELAS) indicates a pro-
gressive encephalomyopathy characterized by repeated
stroke-like events (often involving the posterior cerebral
areas), recurrent headache, exercise intolerance, seizures
and lactic acidosis. Onset can be before the age of 40.
Mutations most frequently associated with this condition
are A3243G [22] and T3271C in tRNA leucine (UUR) in
the mitochondrial genome. Ataxia may be present, but is
not typical [25].
Maternally inherited Leigh syndrome (MILS) has its
onset generally during the first year of life. The patient may
present with motor retardation, hypotonia, ataxia, epileptic
seizures, myoclonus, neuropathy, optic atrophy, pigmen-
tary retinopathy, lactic acidosis and psychomotor regres-
sion. It is usually associated with point mutations in the
gene ATP6 (the mtDNA-encoded subunit of complex V of
the respiratory chain––the ATP synthase), especially at the
T8993G. If the percentage of mutant mtDNA is \90 %
(between 70 and 90 %), the clinical picture is more benign,
later in onset, and characterized by neuropathy, ataxia and
pigmentary retinopathy (NARP syndrome). Marked phe-
notypic differences even between family members have
been reported. ATP6 mutations have also been associated
with cognitive developmental delay, learning disability and
progressive ataxia [25].
Other mtDNA point mutations have been linked to
complex neurological phenotypes including ataxia, and
sequencing of the entire mtDNA (from muscle samples) is
indicated in all unusual neurological syndromes, even in
the absence of clear maternal inheritance.
mtDNA sporadic rearrangements
The sporadic occurrence of a mitochondrial disease, such
as progressive external ophthalmoplegia (PEO) and
Kearns–Sayre syndrome (KSS; ophthalmoplegia associated
with pigmentary retinopathy and cardiac conduction
block), is suggestive of a single, sporadic, mtDNA deletion.
KSS is associated with a single large-scale mtDNA
deletion and is clinically characterized by pigmentary ret-
inopathy and PEO. Associated features are cardiac con-
duction defects and CA. Onset is often before 20 years of
age. Additional features may include growth retardation,
short stature, deafness, muscle weakness, endocrinopathies,
renal tubular dysfunction and hyperlactacidaemia. A dis-
connection of Purkinje cells at the dentate nucleus may
play a role in the pathogenesis of CA in KSS. CA may also
represent a feature of ‘PEO plus’ phenotypes due to single
mtDNA deletions [25].
Polymerase gamma-1 gene-related diseases
Mitochondrial disorders related to nDNA are caused by
mutations in structural components or ancillary proteins of
the electron transport chain, by defects of the membrane
lipid milieu, of coenzyme Q10 biosynthetic genes, and by
defects in intergenomic signalling (associated with mtDNA
depletion or multiple deletions).
It is now well established that defects in mtDNA repli-
cation can lead to mitochondrial dysfunction and disease,
including cerebellar dysfunction and ataxia [25]. DNA
polymerase gamma (POLG) is the only DNA polymerase
in human mitochondria and is essential for mtDNA repli-
cation and repair. Nuclear genes encode POLG subunits 1
and 2 (POLG1 and POLG2).
POLG1 mutations can cause dominant or recessive
disorders, frequently associated with severe and multi-
system involvement. These forms of mitochondrial dis-
order are associated with secondary accumulation of
multiple deletions in mtDNA. Mutations in the POLG1
gene have emerged as one of the most common causes of
inherited mitochondrial disorders in children and adults.
Movement disorders are common [30]. It has recently
been observed that POLG1 mutations are rather common
in Central European ataxia patients, causing ataxia with
PEO (47 %), psychiatric comorbidities (20 %) and epi-
lepsy (14 %) [36].
The most severe manifestations have been associated
with mutations of the ‘spacer’ region of POLG1 (i.e.,
ataxia-myopathy syndrome). In a large study, the clinical
presentation ranged from the neonatal period to late adult
life, with an overlapping phenotypic spectrum from severe
encephalopathy and liver failure to late-onset PEO, ataxia,
myopathy and isolated muscle pain or epilepsy [14]. A
form of chronic POLG1-encephalopathy associated with
the G1399GA and G2243C mutations is characterized by
progressive cerebral and cerebellar atrophy in imaging
studies [41].
High carrier frequency of the W748S POLG1 substitu-
tion was reported in control subjects in Finland, explaining
the high prevalence of ‘mitochondrial recessive ataxia
syndrome’ (MIRAS) in Scandinavia [11]. However,
although A467T and W748S are a common cause of ataxia
in Scandinavia, they are rare in other European regions. It
is, therefore, likely that the high prevalence of MIRAS in
Finland and Norway is due to a founder effect.
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Another POLG-related recessive ataxia is sensory ataxic
neuropathy, dysarthria, and ophthalmoparesis (SANDO),
which results from mitochondrial dysfunction due to
mtDNA deletions in skeletal muscle. Symptoms present
during adulthood [9].
Infantile onset spinocerebellar ataxia
Infantile onset spinocerebellar ataxia (IOSCA) is a severe
autosomal recessively inherited neurodegenerative disorder
characterized by progressive atrophy of the cerebellum,
brainstem and spinal cord and sensory axonal neuropathy.
It is due to recessive mutations in the gene C10orf2
encoding Twinkle, an mtDNA-specific helicase. Interest-
ingly, different mutations in the same gene cause autoso-
mal dominant progressive external ophthalmoplegia
(adPEO) with multiple mtDNA deletions (due to mtDNA
replication pausing or stalling) [25].
Optic atrophy 1 gene-related diseases
A third cause of defects in intergenomic signalling (causing
mtDNA multiple deletions) with ataxia arises from optic
atrophy 1 (OPA1) gene mutations [25]. OPA1 is the most
common cause of autosomal dominant optic atrophy.
Extra-ocular neurological complications are common,
affecting up to 20 % of all mutational carriers. Bilateral
sensorineural deafness beginning in late childhood and
early adulthood are the prominent manifestation, followed
by a combination of ataxia, myopathy, peripheral neurop-
athy and PEO from the third decade of life onwards [25].
Coenzyme Q10 deficiency
Coenzyme Q10 deficiency is a rare autosomal recessive
disease which has been associated with five major syn-
dromes: (1) encephalomyopathy (with recurrent myoglo-
binuria, brain involvement and ragged red fibres); (2)
severe infantile multisystemic disease; (3) CA; (4) Leigh
syndrome (growth retardation, ataxia and deafness); and
(5) isolated myopathy [7]. Primary coenzyme Q10 defi-
ciency due to mutations in ubiquinone biosynthetic genes
(i.e. COQ2, PDSS1, PDSS2, CABC1) has been identified in
patients with the infantile multisystemic and cerebellar
ataxic phenotypes. In contrast, secondary coenzyme Q10
deficiency, due to mutations in genes not directly related to
ubiquinone biosynthesis (i.e. APTX, ETFDH, BRAF), has
been identified in patients with CA, pure myopathy and
cardiofaciocutaneous syndrome [25].
Coenzyme Q10 deficiency with CA has also been
associated with mutations in the CABC1/COQ8/ADCK3
gene [25]. Recently, Gerards and co-workers [10] reported
the first nonsense mutations in CABC1 that most likely led
to complete absence of a functional CABC1 protein and
suggested that CABC1 is an important candidate for
mutation analysis in progressive CA and atrophy on
imaging studies. Patients have a childhood-onset gait ataxia
and cerebellar atrophy with slow progression [34]. Horvath
and co-workers [13] reported a high frequency of ADCK3
mutations (4 out of 22 patients) in a cohort of undiagnosed
ataxias, highlighting the importance of screening for this
potentially treatable form.
Some cases of the ataxic variant of coenzyme Q10
deficiency have been linked to a homozygous mutation in
the aprataxin (APTX) gene, which causes ataxia oculomo-
tor apraxia type 1 (discussed below). The clinical pheno-
type of this disorder is homogeneous and is mainly
characterized by early-onset cerebellar signs, sensory
neuropathy, cognitive decline, and oculomotor deficits. The
relationship between aprataxin, involved in DNA repair,
and coenzyme Q10 deficiency, if any, is still unclear [25].
CA is the most common phenotype of coenzyme Q10
deficiency, with nearly 100 patients reported to date [7].
Other manifestations include neuropathy, seizures, mental
retardation, migraine, psychiatric disorders, muscle weak-
ness and exercise intolerance, congenital hypotonia, upper
motor neuron signs, dystonia and chorea, ptosis and oph-
thalmoplegia, retinitis pigmentosa, optic atrophy, oculo-
motor apraxia, deafness, lipomatosis, Dandy–Walker
syndrome, agenesis of corpus callosum, hypogonadism and
other endocrinological problems, hypoalbuminaemia, and
hypercholesterolaemia [7]. Initial biochemical evaluation
of patients with suspected coenzyme Q10 deficiency should
include blood lactate measurement, although normal values
do not exclude ubiquinone deficiency. Muscle biopsies
occasionally show mitochondrial proliferation or lipid
droplets, but can be normal or show only non-specific
changes. In patients with the ataxic form, muscle biopsies
revealed mitochondrial proliferation, COX-negative fibres,
or lipid accumulation in 15/49, and reduced respiratory
chain enzyme activities in 27/51 [7]. Direct measurement
of coenzyme Q10 in skeletal muscle by high-performance
liquid chromatography is the most reliable test for the
diagnosis [7]. The diagnosis is reinforced by reduced bio-
chemical activities of respiratory chain complexes, in
particular, complexes I ? III and II ? III. Molecular
genetic testing has revealed causative mutations in a small
proportion of patients indicating that screening for DNA
mutations is not yet effective for diagnosing coenzyme
Q10 deficiency, probably because of the large number of
proteins involved in ubiquinone biosynthesis and regula-
tion and of secondary coenzyme Q10 deficiencies [7].
Coenzyme Q10 deficiency is a treatable condition, so
heightened ‘clinical awareness’ about this diagnosis is
essential, especially for paediatricians and infantile neu-
rologists. Varying degrees of coenzyme Q10 deficiency
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cause variable defects of ATP synthesis and oxidative
stress. An early treatment with high-dose coenzyme Q10
may radically change the natural history. Patients with all
forms of coenzyme Q10 deficiency have shown clinical
improvement with oral coenzyme Q10 supplementation,
but cerebral symptoms are only partially ameliorated
(probably because of irreversible structural brain damage
before treatment and because of poor penetration of
coenzyme Q10 across the blood–brain barrier). Patients
were given various doses of coenzyme Q10 ranging from
90 to 2,000 mg daily. The small number of patients pre-
cluded any statistical analysis but improvement was
undoubtedly reported. In several patients coenzyme Q10
supplementation also ameliorated the mitochondrial func-
tion (electron transport chain activities, lactic acid values,
muscle coenzyme Q10 content). The beneficial effects of
exogenous coenzyme Q10 require high doses and long-
term administration.
Hereditary spastic paraparesis with ataxia
Hereditary spastic paraparesis (HSP) describes a hetero-
geneous group of neuro-genetic disorders caused by
degeneration of the corticospinal tracts. The key clinical
findings are lower limb spasticity, with hyperreflexia and
extensor plantar responses [35]. Urinary urgency is also
frequent. Age at onset is extremely variable, from child-
hood through to late adult life. Traditionally, these condi-
tions have been divided into pure HSPs and complicated
HSPs, depending on the presence of adjunctive neurolog-
ical features such as ataxia, thin corpus callosum, periph-
eral neuropathy, distal amyotrophy, retinopathy, optic
atrophy, extrapyramidal signs, cognitive dysfunction,
deafness, and epilepsy [35].
The best-characterized molecular mechanisms in HSPs
are impairment of transport of macromolecules and
organelles, disturbance of mitochondrial function, or
abnormalities of the developing axon [35]. The genetics of
HSP is complex and all Mendelian modes of inheritance
have been described. Most cases of autosomal dominant
HSP are pure, whereas complicated forms tend to be
autosomal recessive; SPG4 (SPAST, spastin), SPG3A and
SPG31 (REEP1) are the most common causes of autosomal
dominant pure HSP [35]. Mutations in the SPG7 gene
(paraplegin) are the most common cause of autosomal
recessive HSP, with both pure and complicated phenotypes
[35], frequently including cerebellar atrophy and cerebellar
signs at the neurological examination [32]. Moreover, a
significant number of apparently sporadic cases have an
SPG mutation.
HSP subtypes which more commonly cause a ‘spastic
ataxia’ phenotype are the recessive forms SPG7 and
SPG15 (and the very rare subtypes due to SPG30 and
SPAX mutations); these conditions enter the differential
diagnosis with Friedreich ataxia and related diseases,
autosomal recessive spastic ataxia of Charlevoix-Saguenay
(ARSACS), and spinocerebellar ataxia (SCA) subtypes
with spasticity (i.e., SCA1, 3, 7, 10, 11, 12) [9].
Autosomal recessive ataxias
Friedreich ataxia
Friedreich ataxia, the most common autosomal recessive
ataxia in the Caucasian population, is due to mutations in
the FXN gene, mostly an expanded GAA intronic triplet
repeat. Age at onset is 5–25 years. Mixed (cerebellar and
sensory) ataxia is the cardinal symptom. The clinical
course is variable, but in general 10–15 years after onset
patients lose the ability to walk, stand and sit without
support. Age at diagnosis, which may incorporate other
genetic and environmental factors, may be more important
than GAA length in predicting cardiomyopathy, scoliosis,
and disease progression [25].
Sensory neurons in the dorsal root ganglia are initially
lost, with secondary degeneration of the spinocerebellar
and pyramidal tracts, as well as of the dorsal columns.
Therefore, Friedreich ataxia is characterized by progressive
gait and limb ataxia, dysarthria, loss of vibration and pro-
prioceptive sense, areflexia, abnormal eye movements, and
pyramidal signs. Other tracts may be involved (i.e., audi-
tory, optic, etc.). During the disease course, hypertrophic
cardiomyopathy may develop. Diabetes, scoliosis, pes ca-
vus, and restless legs syndrome are other possible mani-
festations [25]. MRI of the brain does not reveal cerebellar
atrophy, but mild-to-moderate atrophy of the brain stem
and spinal cord.
The genetic abnormality results in the deficiency of
frataxin, a protein targeted to the mitochondrion which
may represent an activator of oxidative phosphorylation.
Although the exact physiological function of frataxin is
not known, its involvement in iron–sulfur cluster bio-
genesis has been suggested. Current evidence suggests
that loss of frataxin impairs mitochondrial iron handling
and respiratory chain function and contributes to
increased oxidative stress and cellular damage. Further-
more, increased mitochondrial iron uptake coupled with
decreased utilization and release may lead to mitochon-
drial iron loading [25].
Treatment options have been mostly directed at anti-
oxidant protection against mitochondrial damage. Idebe-
none, a coenzyme Q10 derivative, was protective in
fibroblasts from patients with Friedreich ataxia and in
animal models [25]. Early trials have demonstrated that
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low-dose idebenone (5 mg/kg per day) could reduce car-
diac hypertrophy [25]. A randomized, placebo-controlled
trial has been conducted on 48 patients [5]. Treatment with
higher doses of idebenone (up to 45 mg/kg) was generally
well tolerated and was associated with improvement in
neurological function and activities of daily living. The
degree of improvement correlated with the dose of idebe-
none, suggesting that higher doses may be needed to have a
beneficial effect on neurological function [5]. Patients with
Friedreich ataxia should, therefore, be treated with idebe-
none because it is well tolerated and may reduce cardiac
hypertrophy and, at higher doses (up to 45 mg/kg), it may
also improve neurological function.
Ataxia with vitamin E deficiency
Ataxia with vitamin E deficiency (AVED) is a recessive
disorder that presents with a clinically similar phenotype to
Friedreich ataxia, with normal cerebellar features at MRI.
Decreased visual acuity or retinitis pigmentosa may be an
early finding. Cardiomyopathy and diabetes are much less
common than in Friedreich ataxia. The disease is caused by
mutation of the a-tocopherol transfer protein. Serum con-
centrations of vitamin E are low. The mechanism under-
lying this pathogenesis is increased oxidative stress, which
might also be a contributory factor in Friedreich ataxia.
Supplementation with vitamin E stops progression and can
mildly improve CA [8].
Abetalipoproteinaemia
Abetalipoproteinaemia is an ataxic syndrome caused by
mutations in the gene for the large subunit of microsomal
triglyceride transfer protein which functions in the assem-
bly of apolipoprotein-B containing very low density lipo-
proteins and chylomicrons. The neurological phenotype
presents before age 20 years, and is similar to Friedreich
ataxia, but it is also associated with lipid malabsorption,
hypocholesterolaemia, acanthocytosis, and retinitis pig-
mentosa. Treatment involves dietary modification and
vitamin replacement, which may prevent neurological
complications if begun early [8].
Refsum’s disease
Refsum’s disease is a recessive disorder primarily caused
by mutation of the gene for the peroxisomal enzyme phy-
tanoyl-CoA hydroxylase (PHYH) and is clinically charac-
terized by CA, peripheral polyneuropathy, sensorineural
deafness, retinitis pigmentosa and anosmia with skeletal
abnormalities, ichthyosis, renal failure, cardiomyopathy or
arrhythmias. Onset is typically before age 20 years. Phy-
tanic acid accumulates to high levels in body fat, including
myelin. Dietary modifications can stop disease progression
[8].
The presence of cerebellar atrophy and/or clinical find-
ings not typically seen in Friedreich ataxia, such as epi-
lepsy or cognitive or psychiatric symptoms [8], should alert
physicians to consider the following recessive neurometa-
bolic disorders (discussed below) in the differential
diagnosis:
Late-onset Tay–Sachs disease
Tay–Sachs disease is an autosomal recessive untreatable
GM2-gangliosidosis caused by a deficiency of the enzyme
b-hexosaminidase A (HEXA). It is typically a severe
infantile disorder, but the late-onset phenotype presents as
either a childhood-onset or adult-onset disease character-
ized by cerebellar dysfunction, areflexia, proximal muscle
weakness with subsequent muscle atrophy and fascicula-
tions, and psychiatric or behavioural problems. Spasticity,
seizures, and dementia can also be present in the juvenile-
onset form. Cerebellar atrophy on MRI is a typical finding
[8].
Cerebrotendinous xanthomatosis
This disorder is caused by mutation of the mitochondrial
enzyme sterol 27-hydroxylase (CYP27), part of the hepatic
bile acid synthesis pathway, resulting in increases of serum
cholestanol and bile alcohols which deposit in CNS tissues.
Neurological symptoms generally start around age 20 years
and include ataxia with pyramidal or extrapyramidal signs,
sensorimotor peripheral neuropathy, seizures, psychiatric
problems, and dementia. Associated features include
juvenile cataracts, tendon xanthomas, early atherosclerosis,
osteoporosis, and chronic diarrhoea. Neuroimaging studies
show generalized cerebral and cerebellar atrophy as well as
diffuse white matter lesions on MRI. This disease is
treatable by bile acid replacement therapy with chenode-
oxycholic acid.
Niemann–Pick disease type C
Niemann–Pick disease refers to a group of autosomal
recessive lipid storage disorders associated with a variable
degree of neurological manifestations in addition to other
organ involvement. Of interest to neurologists is Niemann–
Pick disease type C (NP-C) because of the association with
neurological manifestations that are not confined to child-
hood [18]. Neurological symptoms vary with age and
include hypotonia, delay in developmental motor mile-
stones, falls, seizures, learning difficulties, ataxia with
cognitive deficits, and psychosis [18, 33]. Other typical
findings are splenomegaly and vertical supranuclear gaze
J Neurol (2014) 261 (Suppl 2):S528–S541 S535
123
palsy [27]. Separate articles in this supplement provide
detailed descriptions of the clinical and psychiatric symp-
toms of NP-C (see article by Nia, this issue) and of the
genetics and relevant diagnostic procedures associated with
this treatable metabolic disorder (see article by Gissen and
Mackay, this issue).
Ataxia telangiectasia
Ataxia telangiectasia results from mutation of a protein
kinase involved in the signal transduction cascade triggered
by DNA damage (ATM). In patients with ataxia telangi-
ectasia, onset of cerebellar dysfunction begins by age
2–3 years and is severely progressive; oculomotor apraxia
is common. Associated features include ocular and cuta-
neous telangiectasias, immunodeficiency, increased risk for
leukaemias and lymphomas. High concentrations of serum
a-fetoprotein are typically found. No effective treatment is
available [8].
Ataxia with oculomotor apraxia type 1 and 2
A review on ocular movement disorders is available sep-
arately in this supplement (see article by Strupp et al. this
issue). Ataxia with oculomotor apraxia type 1 presents
before the age of 10 years with gait and limb ataxia, sen-
sorimotor neuropathy, eye movement abnormalities
including nystagmus, fixation instability, and variable
oculomotor apraxia, extrapyramidal signs, and mild cog-
nitive impairment. Cerebellar atrophy (especially of the
vermis), hypoalbuminaemia, and hypercholesterolaemia
are typical findings. The disease is caused by mutation of
the aprataxin gene (APTX) which plays a part in DNA
repair [8]. In three siblings with mutations in APTX gene,
coenzyme Q10 supplementation was associated with clear
improved ambulation and resolution of seizures in one
patient, but further studies are needed [7].
Ataxia with oculomotor apraxia type 2 has a similar
phenotype to type 1, but age at onset is in the early teens
and laboratory studies show normal albumin and high
serum a-fetoprotein concentrations. Ataxia with oculomo-
tor apraxia type 2 could be the second most common
autosomal recessive ataxia after Friedreich ataxia in the
European population. It is caused by mutations in the gene
for senataxin (SETX), a DNA/RNA helicase implicated in
DNA transcription, DNA repair, and the processing of non-
coding RNAs [8].
ARSACS
ARSACS is due to mutations in the chaperone protein
sacsin (SACS) and is characterized by progressive cere-
bellar dysfunction, pyramidal signs and peripheral
sensorimotor neuropathy with amyotrophy. Onset is typi-
cally at age 1–5 years and MRI shows cerebellar vermian
atrophy [8]. A suggestive MRI finding is the hyperintensity
of the lateral pons merging into the (thickened) middle
cerebellar peduncles [40].
Autosomal recessive cerebellar ataxia type 1
Autosomal recessive cerebellar ataxia type 1 (ARCA1) is a
slowly progressive, adult-onset ataxia with prominent
dysarthria and cerebellar atrophy, caused by mutations in
the very large SYNE1 gene [34]. ARCA1 was first reported
in patients from the province of Quebec (Canada), but was
rarely observed in other populations [29].
A similar form of pure ataxia caused by homozygous
ADCK3 mutations, which has been defined as ARCA2
[34], was discussed above (‘‘Coenzyme Q10 deficiency’’).
Autosomal dominant spinocerebellar ataxias
The designation ‘spinocerebellar ataxias’ (SCAs) indicates
the involvement of at least two systems: the spinal cord and
the cerebellum [6]. SCAs are progressive neurodegenera-
tive diseases with CA, resulting in unsteady gait, clumsi-
ness, and dysarthria. The cerebellar syndrome may be
associated with other neurological signs such as pyramidal
or extrapyramidal signs, ophthalmoplegia, and cognitive
impairment. Onset is usually during the third or fourth
decade of life, but can occur in childhood or old age [6].
Atrophy of the cerebellum and brainstem are most often the
prominent features.
Eleven of the 18 known genes are caused by protein
polyglutamine expansion [i.e., SCA1, SCA2, SCA3, SCA6,
SCA7, SCA17, and dentate-rubro-pallidoluysian atrophy
(DRPLA)]. In general terms, polyglutamine-expanded
proteins have been reported to increase cellular ROS levels
and significantly reduce the mitochondrial electrochemical
gradient, inducing DNA damage. The remaining SCAs are
caused by non-coding expansions, mutations or large
rearrangements in genes with different functions, including
mitochondrial activity (SCA28/AFG3L2) [6].
Gait disorders are the initial symptom in two-thirds of
patients with polyglutamine expansion SCA [6]. With
disease duration, the clinical picture becomes increasingly
complex, and this corresponds to the wide distribution of
the underlying neuropathology. Hyperreflexia and spastic-
ity are more typical of SCA1, SCA3, and SCA7 [6].
Abnormal eye movements are frequently associated with
polyglutamine expansion SCAs. In SCA1, saccade ampli-
tude is increased, resulting in hypermetria and decreased
smooth pursuit gain; in SCA2, saccade velocity is sub-
stantially decreased and the percentage of errors in
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antisaccades is high; in SCA3, gaze-evoked nystagmus and
hypometric saccades are often present, and smooth pursuit
gain decreases greatly; in SCA6, downbeat nystagmus is
frequent, and eye movements are similar to those observed
in patients with SCA3 [6]. A recent study reported that
perverted head-shaking nystagmus could be the most sen-
sitive parameter for SCA6, whereas saccadic intrusions/
oscillations were the most sensitive for SCA3; in contrast, a
paucity of gaze-evoked nystagmus and dysmetric saccades
was more indicative of SCA2 [19].
The presence of associated movement disorders (such as
myoclonus, dystonia, chorea, parkinsonism) can help in the
diagnostic assessment, considering that they are typical of
some forms (e.g. SCA1, 2, 3) [42]. Our group recently
reported levetiracetam-responsive myoclonus in a young
female patient with SCA15 [31]. Some coexisting move-
ment disorders may be linked to the cerebellar pathology
itself (e.g., myoclonus and dystonia), whereas others are
more likely related to extracerebellar pathology, and
imaging and neuropathological data indeed show involve-
ment of other parts of the motor system (substantia nigra,
striatum, pallidum, motor cortex) in some SCA subtypes
[42]. When confronted with a patient with an isolated
movement disorder without ataxia, there is currently no
reason to routinely screen for SCA gene mutations. The
only possible exceptions are SCA2 analysis in autosomal
dominant parkinsonism (particularly in Asian patients) and
SCA17 analysis in the case of a Huntington’s disease-like
presentation without an huntingtin mutation [42].
As with age at onset, the clinical picture of polygluta-
mine expansion SCAs depends on the length of the CAG
repeat expansion. Anticipation is most evident in DRPLA
and SCA7; paternal expansions are more likely to be
unstable during transmission [6].
There are phenotypic differences between polygluta-
mine expansion SCAs and conventional mutation SCAs.
The disease progression is severe and disabling with a life-
threatening course in polyglutamine expansion SCAs, in
contrast with a slowly progressive course in conventional
mutation SCAs, despite early onset [6]. The clinical fea-
tures of autosomal dominant SCAs are summarized in
Table 2.
X-linked ataxias
Fragile X-associated tremor/ataxia syndrome
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a
late-onset neurodegenerative disorder that affects individ-
uals who are carriers of premutation expansions
(55–200 CGG repeats) in the 50 untranslated region of the
FMR1 (fragile X mental retardation 1) gene. This disease is
characterized by a late-onset intention tremor and gait
ataxia, with possible parkinsonism, neuropathy, autonomic
dysfunction, and dementia. Penetrance is incomplete and
higher in males. It is one of the most common hereditary
late-onset CAs, with a frequency of about 1 in 3,000 [34].
Symmetric regions of increased T2 signal intensity in the
middle cerebellar peduncles and adjacent cerebellar white
matter are considered typical of this disease [9]. A recent
survey reported that more than 40 % of patients had no
family history of fragile X syndrome and more than 80 %
had tremor and/or peripheral neuropathy; 60 % of patients
had parkinsonism; corpus callosum splenium hyperinten-
sity was as frequent as middle cerebellar peduncle hyper-
intensity (about 65 %) [1].
X-linked sideroblastic anaemia and ataxia
X-linked sideroblastic anaemia and ataxia (XLSA/A) is a
recessive disorder characterized by an infantile to early
childhood onset of non-progressive CA and mild anaemia
with hypochromia and microcytosis. A gene encoding an
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ATP-binding cassette (ABC7) transporter, mapped to
Xq13, has been linked to this disease. ABC7 localizes to
the mitochondrial inner membrane and is involved in iron
homeostasis [25].
Episodic ataxias
Episodic ataxias are characterized by recurrent, discrete
episodes of vertigo, ataxia, and often migraine headaches
and nausea. The ataxia may or may not be progressive.
Episodic ataxia genes code for ion channels or glutamate
transporters [34]. Episodic ataxia type 1 is clinically
defined by brief episodes of ataxia where the patient is
unaffected in between; it is due to KCNA1 gene mutations.
In episodic ataxia type 2 the attacks can last longer and
there is usually a background ataxia on examination; the
causal gene is CACNA1A. In the interictal interval, myo-
kymia is present in hand muscles when analysed by EMG
in the type 1 form, whereas type 2 patients present with
interictal gaze-evoked nystagmus, downbeat nystagmus,
and other cerebellar ocular motor disorders [9]. There are a
Fig. 2 Differential
neurological signs in autosomal
dominant cerebellar ataxia. SCA
spinocerebellar ataxia (types
1–3, 6, 7, 17), POLG
mitochondrial DNA polymerase
gamma
Fig. 3 Multidisciplinary approach to differential diagnosis of cerebellar ataxia. AFP alpha feta protein, CA cerebellar ataxia, F fibroblasts,
M skeletal muscle, NCS–EMG nerve conduction studies and electromyography
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few other forms that are extremely rare. The first-line
treatment nowadays is 4-aminopyridine; second-line ther-
apies include acetazolamide and diclofenamide [15, 37,
38].
How to treat ataxia
Apart from the availability of specific treatment options for
some of the diseases discussed above, treatment of
degenerative CA remains very difficult [15]. To date, no
medication has been proven effective. Aminopyridines and
acetazolamide, which are beneficial in patients with epi-
sodic ataxia type 2, are the only exception [15]. Amino-
pyridines are also effective in a subset of patients
presenting with downbeat nystagmus [15]. Acetyl-DL-leu-
cine could improve ataxic symptoms in some patients, but
controlled trials are still needed [39]. The mainstays of
treatment for degenerative CA are currently physiotherapy,
occupational therapy, and speech therapy, but evidence-
based guidelines for the physiotherapy of degenerative CA
need to be developed [15].
How to approach a patient with ataxia
Although the majority of disease genes have been found in
the past two decades, over the past 3 years the genetics has
undergone a methodological revolution [34]. New DNA
sequencing technologies allow the study of large propor-
tions of the genome in a rapid and affordable way. Even if
a specific challenge of next-generation sequencing data is
pathogenicity interpretation, a recent study showed that
genetic testing using targeted capture followed by next-
generation sequencing was efficient, cost-effective, and
enabled a molecular diagnosis in many cases with undi-
agnosed ataxia [28]. Exome and targeted sequencing has
recently identified a few new genes causing ataxia (e.g.
TGM6, ANO10, SYT14, and rundataxin) [34]. This
approach is likely to continue to discover new ataxia genes
and make screening of causative genes more effective in
terms of cost and time to diagnosis.
However, most cases of CA are sporadic, and the
diagnostic work-up to date remains a challenge, with at
least 50 % of patients remaining without a molecular
diagnosis.
Detailed anamnesis and deep investigation of the family
pedigree are usually enough to discriminate between
acquired and genetic conditions (Fig. 1; Table 1). Once the
acquired conditions have been ruled out, and the suspicion
of an inherited condition raised, the pedigree analysis
might already be indicative of the pattern of inheritance.
In the case of autosomal dominant CA, molecular test-
ing should be guided by taking into account the main
associated symptoms (Fig. 2) [9].
In sporadic cases, we propose here a multidisciplinary
approach (Fig. 3), where the neurologist should always
deal at least with the following points to get out of the
ataxic maze: (1) onset and clinical course of the disease;
(2) associated clinical features (not only neurological, but
also psychiatric, ophthalmological, skin observation, etc.);
(3) neurophysiological parameters, with special attention to
the nerve conduction studies and the occurrence of
peripheral neuropathy (sensory or sensory motor neuropa-
thy) or not; (4) neuroimaging results (presence or absence
of cerebellar atrophy and leukodystrophy) [43]; (5) labo-
ratory findings. Regarding the laboratory tests, even though
not all of the presented tests are available in routine lab-
oratories, detailed research of at least some of those
parameters may lead the physician to a correct diagnosis.
We should all be aware that a late-onset sporadic ataxia, in
which other possible causes have been excluded by fol-
lowing the proposed steps, might be attributable to a
metabolic disorder (e.g. NP-C or mitochondrial diseases),
which in some instances may be treatable.
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